- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01134939
Non-interventional Observational Study With Viramune® in HIV to Evaluate Gender Specific Data
Non-interventional Observational Study With Viramune® Plus Antiretroviral Backbone Combination in HIV-infected Women and Male Patients. Gender Specific Evaluation of Data.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Time Perspective:
retro- and prospective
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
-
Aachen, Allemagne
- Boehringer Ingelheim Investigational Site 23
-
Berlin, Allemagne
- Boehringer Ingelheim Investigational Site 10
-
Berlin, Allemagne
- Boehringer Ingelheim Investigational Site 11
-
Berlin, Allemagne
- Boehringer Ingelheim Investigational Site 14
-
Berlin, Allemagne
- Boehringer Ingelheim Investigational Site 19
-
Berlin, Allemagne
- Boehringer Ingelheim Investigational Site 26
-
Berlin, Allemagne
- Boehringer Ingelheim Investigational Site 28
-
Berlin, Allemagne
- Boehringer Ingelheim Investigational Site 33
-
Berlin, Allemagne
- Boehringer Ingelheim Investigational Site 4
-
Berlin, Allemagne
- Boehringer Ingelheim Investigational Site 5
-
Berlin, Allemagne
- Boehringer Ingelheim Investigational Site 8
-
Berlin, Allemagne
- Boehringer Ingelheim Investigational Site 9
-
Chemnitz, Allemagne
- Boehringer Ingelheim Investigational Site 31
-
Dortmund, Allemagne
- Boehringer Ingelheim Investigational Site 29
-
Düsseldorf, Allemagne
- Boehringer Ingelheim Investigational Site 27
-
Frankfurt, Allemagne
- Boehringer Ingelheim Investigational Site 17
-
Frankfurt, Allemagne
- Boehringer Ingelheim Investigational Site 1
-
Freiburg, Allemagne
- Boehringer Ingelheim Investigational Site 2
-
Giessen, Allemagne
- Boehringer Ingelheim Investigational Site 34
-
Hamburg, Allemagne
- Boehringer Ingelheim Investigational Site 22
-
Hamburg, Allemagne
- Boehringer Ingelheim Investigational Site 6
-
Hannover, Allemagne
- Boehringer Ingelheim Investigational Site 12
-
Hannover, Allemagne
- Boehringer Ingelheim Investigational Site 16
-
Karlsruhe, Allemagne
- Boehringer Ingelheim Investigational Site 32
-
Koblenz, Allemagne
- Boehringer Ingelheim Investigational Site 15
-
Köln, Allemagne
- Boehringer Ingelheim Investigational Site 25
-
Leipzig, Allemagne
- Boehringer Ingelheim Investigational Site 21
-
München, Allemagne
- Boehringer Ingelheim Investigational Site 20
-
München, Allemagne
- Boehringer Ingelheim Investigational Site 24
-
München, Allemagne
- Boehringer Ingelheim Investigational Site 3
-
München, Allemagne
- Boehringer Ingelheim Investigational Site 7
-
Münster, Allemagne
- Boehringer Ingelheim Investigational Site 13
-
Osnabrück, Allemagne
- Boehringer Ingelheim Investigational Site 18
-
Stuttgart, Allemagne
- Boehringer Ingelheim Investigational Site 30
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion criteria:
The inclusion criteria for treatment with Viramune plus other antiretroviral combination drugs are to be based on the current Information for Healthcare Professionals/SPC
Exclusion criteria:
The inclusion criteria for treatment with Viramune plus other antiretroviral combination drugs are to be based on the current Information for Healthcare Professionals/SPC
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: Cohorte
Cohortes et interventions
Groupe / Cohorte |
---|
HIV-infected women and men
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Number of Patients With Virologic Response (VR) After 36 Months
Délai: 36 months
|
VR is defined as HIV viral load of < 50 copies/mL before month 36 and without subsequent rebound or change of ARV therapy. A rebound is defined by two consecutive measurements of VL ≥ 50 copies/ml, at least two weeks apart. A change of ARV therapy is defined as a permanent discontinuation of Viramune®. A change in the background therapy due to toxicity or intolerance is not considered failure for the analysis. Therefore, a patient remains a treatment responder in this case if all other criteria are fulfilled. A rebound is defined by two consecutive measurements of VL ≥ 50 copies/ml, at least two weeks apart, after two consecutive measurements of VL< 50 copies/ml. |
36 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Changes in the Viral Load After 36 Months From Baseline
Délai: Baseline and 36 months
|
The change in the log10 viral load from baseline after 36 months was calculated by subtracting the baseline value from the value after 36 months.
Therefore, a negative change represents a decrease in viral load.
|
Baseline and 36 months
|
Changes in the CD4+ Cell Count After 36 Months From Baseline
Délai: Baseline and 36 months
|
The change in the Cluster of differentiation 4 (CD4+) cell count from baseline after 36 months was calculated by subtracting the baseline value from the value after 36 months.
Therefore, a positive change represents an increase in CD4+ cell count.
|
Baseline and 36 months
|
Changes in the Laboratory Data (Total Cholesterol) After 36 Months From Baseline
Délai: Baseline and 36 months
|
The changes in the laboratory data (Total Cholesterol) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months.
Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .
|
Baseline and 36 months
|
Changes in the Laboratory Data (HDL Cholesterol) After 36 Months From Baseline
Délai: Baseline and 36 months
|
The changes in the laboratory data ( High density protein (HDL) Cholesterol) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months.
Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .
|
Baseline and 36 months
|
Changes in the Laboratory Data (LDL Cholesterol) After 36 Months From Baseline
Délai: Baseline and 36 months
|
The changes in the laboratory data (Low density protein (LDL) Cholesterol) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months.
Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .
|
Baseline and 36 months
|
Changes in the Laboratory Data (Triglycerides) After 36 Months From Baseline
Délai: Baseline and 36 months
|
The changes in the laboratory data (Triglycerides) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months.
Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .
|
Baseline and 36 months
|
Changes in the Laboratory Data (Blood Glucose) After 36 Months From Baseline
Délai: Baseline and 36 months
|
The changes in the laboratory data (Blood Glucose) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months.
Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .
|
Baseline and 36 months
|
Changes in the Laboratory Data ( ALT) After 36 Months From Baseline
Délai: Baseline and 36 months
|
The changes in the laboratory data (Alanine transaminase (ALT)) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months.
Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .
|
Baseline and 36 months
|
Changes in the Laboratory Data (AST) After 36 Months From Baseline
Délai: Baseline and 36 months
|
The changes in the laboratory data (Aspartate transminase (AST)) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months.
Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .
|
Baseline and 36 months
|
Changes in the Laboratory Data (Gamma-GT) After 36 Months From Baseline
Délai: Baseline and 36 months
|
The changes in the laboratory data (Gamma glutamyl transferase (Gamma GT)) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months.
Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .
|
Baseline and 36 months
|
Changes in the Laboratory Data (Creatinine) After 36 Months From Baseline
Délai: Baseline and 36 months
|
The changes in the laboratory data (Creatinine) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months.
Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .
|
Baseline and 36 months
|
Changes in the Laboratory Data (Haemoglobin) After 36 Months From Baseline
Délai: Baseline and 36 months
|
The changes in the laboratory data (Haemoglobin) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months.
Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .
|
Baseline and 36 months
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Infections par virus à ARN
- Maladies virales
- Infections
- Infections transmissibles par le sang
- Maladies transmissibles
- Maladies sexuellement transmissibles, virales
- Maladies sexuellement transmissibles
- Infections à lentivirus
- Infections à rétroviridae
- Syndromes d'immunodéficience
- Maladies du système immunitaire
- Infections à VIH
Autres numéros d'identification d'étude
- 1100.1536
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Infections à VIH
-
Icahn School of Medicine at Mount SinaiIRRASRecrutementHémorragie intraventriculaire (HIV)États-Unis
-
Yale UniversityComplétéPrématurité | Nourrissons de très faible poids à la naissance | Hémorragie intraventriculaire (HIV) | Saignement dans le cerveauÉtats-Unis
-
West Virginia UniversityInscription sur invitationInfection de la peau et des tissus mous | Infection gastro-intestinale | Infection pulmonaire | Infection des os et des articulations | Infection endovasculaire | Infection génito-urinaireÉtats-Unis
-
Radboud University Medical CenterSint MaartenskliniekActif, ne recrute pasInfection du site opératoire | Infection articulaire | Infection, site chirurgical | Prothèse Infection Hanche et Genou | Infection liée aux prothèses | InfectionProPays-Bas
-
Croydon Health Services NHS TrustComplétéInfection du site opératoire | Infection de la plaie | Césarienne; Infection | Infection périnéaleRoyaume-Uni
-
Taipei Medical University WanFang HospitalInconnue
-
Ondine Biomedical Inc.ComplétéInfection du site opératoire | Infection nosocomiale | Infection associée aux soins de santéÉtats-Unis
-
Angela BiancoStryker NordicRésiliéCésarienne | Infection du site opératoire | Infection nosocomialeÉtats-Unis
-
Leiden University Medical CenterRadboud University Medical Center; University Medical Center Groningen; Erasmus... et autres collaborateursRecrutementInfection prothétique-articulaire | Infection de la hanche | Infection; Genou, ArticulationPays-Bas
-
Cairo UniversityRecrutementInfection postopératoire | Complications de la césarienne | Infection vaginaleEgypte